Metraipolis › archive › dc_16766f3dec44

Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancer — Europe PMC PMID:42095602

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42095602
DOI
10.1093/oncolo/oyag182
License (as archived)
solo-consultazione
Archived
2026-11-02T21:33:17.972Z
SHA-256 of the archived text
5b8951865082836b77e5eb3590d00772bf06d8beb4a9dc9793b71149eae5fbf3
Stable URL of this page
https://metraipolis.com/documento/dc_16766f3dec44

How to cite

Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancer — Europe PMC PMID:42095602 — Europe PMC (en), https://europepmc.org/article/MED/42095602 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_16766f3dec44 (Metraipolis archive dc_16766f3dec44, sha256 5b8951865082836b77e5eb3590d00772bf06d8beb4a9dc9793b71149eae5fbf3)
BibTeX
@misc{dc16766f3dec44,
  title = {Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancer — Europe PMC PMID:42095602},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42095602},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_16766f3dec44; sha256 5b8951865082836b77e5eb3590d00772bf06d8beb4a9dc9793b71149eae5fbf3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42095602. Agents can read the archived copy with the MCP tool read_document.